Peptide Education
Peptide Dosage Chart: Where Dosing Stands for Common Peptides

Searches for peptide dosages usually expect a single table of numbers. The honest answer is that peptides fall into two very different groups. A small number are FDA-approved drugs with labeled doses, established through clinical trials. Most of the peptides discussed in wellness and longevity medicine are not approved for any indication, have no labeled dose, and are dosed at the prescriber's discretion based on a limited evidence base.
This peptide dosage chart reflects that difference rather than hiding it. For approved products it lists the labeled dosing where it is well established. For everything else it says plainly that dosing is prescriber-determined and points to the page where that compound is covered in detail.
Educational content for licensed prescribers and their patients. It is not medical advice and does not replace the instructions on the dispensing pharmacy's label or your prescriber's directions.
How to Read This Chart
- FDA-approved means an approved drug product exists with a prescribing label. Labeled doses apply to the approved product for its labeled indication; compounded or off-label use is a separate question.
- Prescriber-determined means there is no approved labeled dose. Any dose is an individualized clinical decision, and published protocols vary.
- Regulatory status summarizes compounding status as of Newtropin's most recent coverage. It changes; check the FDA peptide status tracker for the current position.
Peptide Dosage Chart
| Peptide | Approval status | Dosing | Where it's covered |
|---|---|---|---|
| Semaglutide | FDA-approved (e.g. Ozempic, Wegovy) | Labeled weekly subcutaneous dosing with gradual titration (oral forms exist with separate labeled dosing); for Wegovy, escalation from 0.25 mg toward a 2.4 mg weekly maintenance dose | [Semaglutide](/peptides/semaglutide) |
| Tirzepatide | FDA-approved (e.g. Mounjaro, Zepbound) | Labeled weekly subcutaneous dosing starting at 2.5 mg, increased in 2.5 mg steps; maximum 15 mg weekly | [Tirzepatide](/peptides/tirzepatide) |
| Tesamorelin | FDA-approved (Egrifta) for HIV-associated abdominal fat | Labeled once-daily subcutaneous dosing for the approved indication | [Tesamorelin dosage](/blog/tesamorelin-dosage) |
| Bremelanotide (PT-141) | FDA-approved (Vyleesi) for premenopausal HSDD | Labeled 1.75 mg subcutaneous, as needed, no more than once in 24 hours | [PT-141](/peptides/pt-141) |
| Retatrutide | Investigational — not FDA-approved | No labeled dose; dosing studied only in clinical trials | [Retatrutide](/peptides/retatrutide) |
| Sermorelin | Previously approved (Geref), no longer marketed | Prescriber-determined | [Sermorelin dosage](/blog/sermorelin-dosage) |
| CJC-1295 + Ipamorelin | Not FDA-approved | No established dose; CJC-1295 has no established 503A eligibility — see page | [CJC-1295 + ipamorelin dosing](/blog/cjc-1295-ipamorelin-dosage) |
| Ipamorelin | Not FDA-approved | Prescriber-determined | [Ipamorelin](/peptides/ipamorelin) |
| IGF-1 LR3 | Not FDA-approved | No established human dose; 503A eligibility not established — see page | [IGF-1 LR3](/peptides/igf-1-lr3) |
| BPC-157 | Not FDA-approved | Prescriber-determined; see compounding status | [BPC-157](/peptides/bpc) |
| TB-500 | Not FDA-approved | Prescriber-determined; see compounding status | [TB-500 half-life and dosing](/blog/tb-500-half-life-sequence-dosing) |
| KPV | Not FDA-approved | Prescriber-determined; see compounding status | [KPV dosing](/blog/kpv-half-life-dosing-sleep-benefits) |
| GHK-Cu | Not FDA-approved as a drug | Prescriber-determined | [GHK-Cu dosage](/blog/ghk-cu-dosage) |
| Testagen | Not FDA-approved | Prescriber-determined | [Testagen dosage](/blog/testagen-dosage-and-protocol-guide) |
| Epitalon | Not FDA-approved | Prescriber-determined; see compounding status | [Epitalon](/peptides/epitalon) |
| MOTS-c | Not FDA-approved | Prescriber-determined; see compounding status | [MOTS-c](/peptides/mots-c) |
| Semax | Not FDA-approved in the US | Prescriber-determined; see compounding status | [Semax](/peptides/semax) |
| Selank | Not FDA-approved in the US | Prescriber-determined | [Selank](/peptides/selank) |
| NAD+ | Not an FDA-approved drug product for these uses | Prescriber-determined | [NAD+](/peptides/nad-plus) |
| AOD-9604 | Not FDA-approved | Prescriber-determined | [AOD-9604](/peptides/aod) |
Labeled doses above are summaries. The full prescribing information for each approved product governs, including titration schedules, dose adjustments, and contraindications.
Why So Many Peptides Have No Standard Dose
Licensed Healthcare Practitioners
6,500+ physician-grade product SKUs, bulk-tier pricing, and direct shipping to your practice. NPI verified, no consumer access.
A labeled dose comes out of dose-finding and pivotal trials reviewed by the FDA. Most wellness peptides have never been through that process. Their evidence base is largely preclinical, with small or early-phase human studies at most. The doses circulating online are often extrapolated from animal work or copied between sources with no clear origin.
That is why this chart does not reproduce them. A prescriber deciding on a dose should weigh the specific compound's evidence, the patient, the formulation and route, and the preparation's concentration — the detail each linked page covers.
Compounding Status Matters Too
Whether a peptide can be lawfully compounded is a separate question from whether it has a labeled dose. FDA's briefing documents for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting proposed not adding BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Epitalon, or Semax to the 503A Bulks List. Other peptides, including sermorelin and ipamorelin, remain under evaluation. Our explainer on the July 2026 PCAC decision covers what that means in practice, and the tracker is updated as the situation changes.
Doses, Concentrations, and Syringe Units
A prescribed dose still has to be converted into a volume based on how the vial was reconstituted. That arithmetic is covered in how to reconstitute peptides, and the peptide calculator does it automatically.
Frequently Asked Questions
Is there a standard peptide dosage chart?
Only for FDA-approved peptide drugs, which have labeled doses. Most peptides used in wellness medicine are not approved and have no standard dose; dosing is determined by the prescriber.
Why doesn't this chart list doses for BPC-157 or TB-500?
Neither has an FDA-approved labeled dose, and the human dosing evidence is limited. Reproducing numbers from unverified sources would present them with more authority than the evidence supports. The linked pages discuss what has been published.
Where do the doses on peptide websites come from?
Often from animal studies, small early-phase trials, or other websites, with the original source unclear. Treat them as unverified unless they trace back to a label or published clinical study.
Does a labeled dose apply to a compounded version?
A labeled dose applies to the approved product for its labeled indication. Compounded preparations and off-label uses are clinical decisions for the prescriber.
How do I turn a dose into syringe units?
Divide the dose by the vial's concentration to get mL, then multiply by 100 for a U-100 syringe. The peptide calculator does this for you.
More from the blog
Continue reading

GHK-Cu Dosage: Topical vs Injectable and What the Evidence Supports
How GHK-Cu dosage differs by route, why no dose is FDA-labeled, what drives prescriber decisions, and the copper and zinc safety checks that matter.
Sep 25, 2026

Tesamorelin Dosage: Labeled Dosing Per Day, Administration, and Monitoring
Tesamorelin dosage per day as labeled for Egrifta, how it is administered, how response is judged, what to monitor, and how off-label use differs.
Sep 25, 2026

Sermorelin Dosage: Timing, Frequency, Titration, and Monitoring
How sermorelin dosing protocols are structured: bedtime timing, fasting, frequency, IGF-1-guided titration, duration, and what prescribers monitor.
Sep 25, 2026
For Licensed Providers
